GlobeNewswire 2/22/2022 Oxurion NV announces 2021 Full Year Results and 2022 Outlook
GlobeNewswire 2/14/2022 Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis...
GlobeNewswire 2/11/2022 Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiog...
GlobeNewswire 2/8/2022 Oxurion to Participate in the 2022 BIO CEO and Investor Conference
GlobeNewswire 1/18/2022 OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference
GlobeNewswire 1/7/2022 Oxurion Provides Update on Clinical Pipeline Progress
GlobeNewswire 1/4/2022 OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
GlobeNewswire 11/30/2021 Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEG...
GlobeNewswire 11/24/2021 OXURION to Present at the Ophthalmology Day at BTIG
GlobeNewswire 11/22/2021 OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventur...
GlobeNewswire 11/15/2021 OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrat...
GlobeNewswire 11/4/2021 Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommen...
GlobeNewswire 10/14/2021 AGTC Announces Two Key Leadership Team Appointments
GlobeNewswire 10/13/2021 Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment o...
GlobeNewswire 10/11/2021 OXURION - Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Specialists ...
GlobeNewswire 10/5/2021 Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire 10/5/2021 OXURION to Present at the Lytham Partners Fall 2021 Investor Conference
GlobeNewswire 9/30/2021 OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of ...
GlobeNewswire 9/9/2021 Oxurion NV Business & Financial Update – H1 2021
GlobeNewswire 9/9/2021 Usio to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
GlobeNewswire 9/9/2021 Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conf...
GlobeNewswire 9/8/2021 OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress
GlobeNewswire 8/17/2021 Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME i...
GlobeNewswire 8/16/2021 Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of...
GlobeNewswire 8/5/2021 OXURION to Participate in Upcoming Investor Meetings